Iconovo's innovative and patent-protected inhalers enables the development of new efficacious patient-friendly medicine.
Iconovo AB
Tillverkning av läkemedel
Lund, Skåne County 3 126 följare
We bring inhalation expertise to your business
Om oss
Iconovo is a leading Swedish CDMO company, offering innovative and effective inhalation platforms to the international pharmaceutical industry. We have several types of patented dry powder inhalers that can create significant commercial opportunities for the development of both new pharmaceuticals and generic medicine. Our strength is our inhouse capabilities with full control over both device development and formulation, meaning less risk and faster time to market.
- Webbplats
-
https://www.iconovo.se
Extern länk för Iconovo AB
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Lund, Skåne County
- Typ
- Publikt aktiebolag
- Grundat
- 2013
- Specialistområden
- Device development, DPI och Inhalation
Adresser
-
Primär
Få vägbeskrivning
Ideongatan 3b
Lund, Skåne County 22370, SE
Anställda på Iconovo AB
Uppdateringar
-
Want to learn more about Iconovo or just get the latest update? Johan Wäborg, CEO at Iconovo will present Iconovo at Carnegies småbolagsdag at 11:05 on Thursday 28th of November. Please follow the link below to listen to the stream! https://lnkd.in/dVuN_ydc
-
-
Iconovo is raising capital in a directed issue. Johan Wäborg, CEO at Iconovo, gave a presentation at Redeye exploring what Iconovo is doing and what value our exciting key projects can deliver in the near future. https://lnkd.in/dC2E9Vnb
-
-
Once again a GLP-1 product, this time Lilly's tirzepatide shows incredibly good treatment results. When treating pre-diabetic patients, 99% were still diabetes-free after 3 years. But they need to remain on treatment. Iconovo wants to replace the injections with intranasal inhalations. Releasing patients from the tyrrany of the GLP-1 syringe. https://lnkd.in/de5s5waD
-
-
Iconovo AB omdelade detta
On behalf of Iconovo and Johan Wäborg, Thank You for your Birthday wishes on our festive 10-year anniversary last Friday! 🎉 🎈 😄 We are looking forward to the next successful decade with exceptional Dry Powder Inhalers and outstanding related services!
-
-
Iconovo is raising new capital to support its exciting projects in the field of inhalation. BIOSTOCK interviewed Johan Wäborg, CEO at Iconovo, with the introductory text: "An intranasal obesity treatment under development, a generic challenger to the asthma product Symbicort and discussions with potential partners are on the agenda for Iconovo". Read the full article at BIOSTOCK homepage (in Swedish only) https://lnkd.in/dVhHsvBd
-
Iconovo is proud to announce that the company's development partner Amneal Pharmaceuticals has completed a clinical pharmacokinetic pilot study comparing ICOres budesonide/formoterol and Symbicort Turbuhaler. The results from the study indicate that ICOres budesonide/formoterol will meet the criteria for demonstrating bioequivalence in an appropriately designed and powered study. The study represents an important step ahead of the initiation of a registration study of the product and Iconovo will proceed according to plan. https://lnkd.in/dJrWse-7
-
Liknande sidor
Finansiering
Iconovo AB
4 rundor totalt
![]()
Swelife
Se mer info på crunchbase
Senaste finansieringsrunda
Anslag
Extern Crunchbase Link för sista finansieringsrundan
50 585,00 US$
Investerare